PF-00562271FAK/Pyk2 inhibitor,potent and ATP-competitive CAS# 939791-38-5 |
- PND-1186
Catalog No.:BCC1866
CAS No.:1061353-68-1
- CEP-37440
Catalog No.:BCC5145
CAS No.:1391712-60-9
- PF-431396
Catalog No.:BCC3971
CAS No.:717906-29-1
- PF-562271
Catalog No.:BCC3674
CAS No.:717907-75-0
- TAE226 (NVP-TAE226)
Catalog No.:BCC3885
CAS No.:761437-28-9
- PF-573228
Catalog No.:BCC4496
CAS No.:869288-64-2
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 939791-38-5 | SDF | Download SDF |
| PubChem ID | 16118986 | Appearance | Powder |
| Formula | C27H26F3N7O6S2 | M.Wt | 665.66 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Synonyms | PF562271 besylate; PF 562271 besylate | ||
| Solubility | DMSO : 21.4 mg/mL (32.15 mM; Need ultrasonic and warming) | ||
| Chemical Name | benzenesulfonic acid;N-methyl-N-[3-[[[2-[(2-oxo-1,3-dihydroindol-5-yl)amino]-5-(trifluoromethyl)pyrimidin-4-yl]amino]methyl]pyridin-2-yl]methanesulfonamide | ||
| SMILES | CN(C1=C(C=CC=N1)CNC2=NC(=NC=C2C(F)(F)F)NC3=CC4=C(C=C3)NC(=O)C4)S(=O)(=O)C.C1=CC=C(C=C1)S(=O)(=O)O | ||
| Standard InChIKey | LKLWTLXTOVZFAE-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C21H20F3N7O3S.C6H6O3S/c1-31(35(2,33)34)19-12(4-3-7-25-19)10-26-18-15(21(22,23)24)11-27-20(30-18)28-14-5-6-16-13(8-14)9-17(32)29-16;7-10(8,9)6-4-2-1-3-5-6/h3-8,11H,9-10H2,1-2H3,(H,29,32)(H2,26,27,28,30);1-5H,(H,7,8,9) | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | PF-00562271, the benzenesulfonate salt of PF-562271, is a potent, ATP-competitive, reversible inhibitor of FAK with IC50 of 1.5 nM, ~10-fold less potent for Pyk2 than FAK and >100-fold selectivity against other protein kinases, except for some CDKs. | |||||
| Targets | FAK | Pyk2 | ||||
| IC50 | 1.5 nM | 14 nM | ||||
PF-00562271 Dilution Calculator
PF-00562271 Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 1.5023 mL | 7.5113 mL | 15.0227 mL | 30.0454 mL | 37.5567 mL |
| 5 mM | 0.3005 mL | 1.5023 mL | 3.0045 mL | 6.0091 mL | 7.5113 mL |
| 10 mM | 0.1502 mL | 0.7511 mL | 1.5023 mL | 3.0045 mL | 3.7557 mL |
| 50 mM | 0.03 mL | 0.1502 mL | 0.3005 mL | 0.6009 mL | 0.7511 mL |
| 100 mM | 0.015 mL | 0.0751 mL | 0.1502 mL | 0.3005 mL | 0.3756 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
PF-562271 is a potent, ATP-competitive and reversible inhibitor of both focal adhesion kinase (FAK), a non-receptor tyrosine kinase involved in a variety of cellular events, and proline-rich tyrosine kinase 2 (Pyk2), an FAK homolog containing 48% amino acid identity, with half maximal inhibitory concentration (IC50) of 1.5 nmol/L and 14 nmol/L respectively. As a potential therapeutic agent either alone or in combination with other agents for the treatment of cancer, PF-562271 has been reported to effectively inhibit the proliferation of tumors in both xenograft and transgenic mouse models, in which it dose-dependently inhibits FAK phosphorylation in tumor-bearing mice with half maximal effective concentration (EC50) of 93 ng/mL.
References:
[1]Stokes JB, Adair SJ, Slack-Davis JK, Walters DM, Tilghman RW, Hershey ED, Lowrey B, Thomas KS, Bouton AH, Hwang RF, Stelow EB, Parsons JT, Bauer TW. Inhibition of focal adhesion kinase by PF-562,271 inhibits the growth and metastasis of pancreatic cancer concomitant with altering the tumor microenvironment. Mol Cancer Ther. 2011 Nov;10(11):2135-45. doi: 10.1158/1535-7163.MCT-11-0261. Epub 2011 Sep 8.
[2]Roberts WG, Ung E, Whalen P, Cooper B, Hulford C, Autry C, Richter D, Emerson E, Lin J, Kath J, Coleman K, Yao L, Martinez-Alsina L, Lorenzen M, Berliner M, Luzzio M, Patel N, Schmitt E, LaGreca S, Jani J, Wessel M, Marr E, Griffor M, Vajdos F. Antitumor activity and pharmacology of a selective focal adhesion kinase inhibitor, PF-562,271. Cancer Res. 2008 Mar 15;68(6):1935-44. doi: 10.1158/0008-5472.CAN-07-5155.
- [Ac-Tyr1,D-Phe2]GRF 1-29, amide (human)
Catalog No.:BCC5719
CAS No.:93965-89-0
- Fluvastatin Sodium
Catalog No.:BCC2317
CAS No.:93957-55-2
- Fluvastatin
Catalog No.:BCC1579
CAS No.:93957-54-1
- Toonaciliatin M
Catalog No.:BCN7881
CAS No.:93930-04-2
- Hirsutanonol 5-O-glucoside
Catalog No.:BCN4485
CAS No.:93915-36-7
- FIPI
Catalog No.:BCC7721
CAS No.:939055-18-2
- 9-Oxo-2,7-bisaboladien-15-oic acid
Catalog No.:BCN4484
CAS No.:93888-59-6
- Isochamaejasmine
Catalog No.:BCN3128
CAS No.:93859-63-3
- KU-0063794
Catalog No.:BCC2484
CAS No.:938440-64-3
- ATPγS tetralithium salt
Catalog No.:BCC7855
CAS No.:93839-89-5
- 22-beta-Acetoxyglycyrrhizin
Catalog No.:BCN7904
CAS No.:938042-17-2
- 3-Prenyl-2,4,6-trihydroxybenzophenone
Catalog No.:BCN1303
CAS No.:93796-20-4
- ACTB-1003
Catalog No.:BCC5587
CAS No.:939805-30-8
- BI 6015
Catalog No.:BCC6249
CAS No.:93987-29-2
- p53 and MDM2 proteins-interaction-inhibitor chiral
Catalog No.:BCC1830
CAS No.:939981-37-0
- RG7112
Catalog No.:BCC1894
CAS No.:939981-39-2
- p53 and MDM2 proteins-interaction-inhibitor racemic
Catalog No.:BCC1831
CAS No.:939983-14-9
- Synephrine
Catalog No.:BCN6308
CAS No.:94-07-5
- Benzocaine
Catalog No.:BCC4636
CAS No.:94-09-7
- Propylparaben
Catalog No.:BCN8416
CAS No.:94-13-3
- Sodium 4-amiropparaty Hyalrate
Catalog No.:BCC3855
CAS No.:94-16-6
- Benzyl 4-hydroxybenzoate
Catalog No.:BCC8869
CAS No.:94-18-8
- Chlorpropamide
Catalog No.:BCC4647
CAS No.:94-20-2
- Tetracaine
Catalog No.:BCC9175
CAS No.:94-24-6
Safety, pharmacokinetic, and pharmacodynamic phase I dose-escalation trial of PF-00562271, an inhibitor of focal adhesion kinase, in advanced solid tumors.[Pubmed:22454420]
J Clin Oncol. 2012 May 1;30(13):1527-33.
PURPOSE: PF-00562271 is a novel inhibitor of focal adhesion kinase (FAK). The objectives of this study were to identify the recommended phase II dose (RP2D) and assess safety and tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity of PF-00562271. PATIENTS AND METHODS: Part 1 was a dose escalation without and with food. Part 2 enrolled specific tumor types in an expansion at the RP2D and also assessed the effect of PF-00562271 on single-dose midazolam PK in a subgroup of patients. RESULTS: Ninety-nine patients (median age, 60 years; 98% with Eastern Cooperative Oncology Group performance status of 0 or 1) were treated in 12 fasting and three fed cohorts. The 125-mg twice-per-day fed dose was deemed the maximum-tolerated dose (MTD) and RP2D. Grade 3 dose-limiting toxicities included headache, nausea/vomiting, dehydration, and edema. Nausea was the most frequently observed toxicity (60% of patients, all grades 1 or 2 at RP2D). PF-00562271 exposure increased with increasing dose; serum concentration-time profiles showed characteristic nonlinear disposition. Steady-state exposures were reached within 1 week. On coadministration, geometric mean values of midazolam maximal observed serum concentration and area under the serum concentration-time curve increased by 60% and more than two-fold, respectively. Of 14 patients evaluable by [(18)F]fluorodeoxyglucose positron emission tomography in the expansion cohorts, seven metabolic responses were observed. With conventional imaging, 31 patients had stable disease at first restaging scans, and 15 of these remained stable for six or more cycles. CONCLUSION: The MTD and RP2D of PF-00562271 is 125 mg twice per day with food. PF-00562271 displayed time- and dose-dependent nonlinear PK and is likely a potent CYP 3A inhibitor. This first-in-class study supports further investigation of FAK as a promising therapeutic target.
